Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    10,988 result(s) found. Displaying page 335 of 550.
    «« First « Previous 331  332  333  334  335  336  337  338  339  Next» Last»»
    EudraCT Number: 2010-021397-12 Sponsor Protocol Number: M0003-C202 Start Date*: 2010-11-23
    Sponsor Name:Shire-Movetis NV
    Full Title: An explorative, randomized, placebo-controlled, double-blind, parallel-group trial, to evaluate the pharmacodynamic effect of M0003 on reflux parameters in subjects with gastroesophageal reflux dis...
    Medical condition: Gastrointestinal esophageal reflux disease (GERD) refractory to proton pump inhibitor therapy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10017885 Gastrooesophageal reflux disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) DE (Prematurely Ended) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004806-17 Sponsor Protocol Number: PQ-313-002 Start Date*: 2018-05-18
    Sponsor Name:Wings Therapeutics Inc.
    Full Title: A first in human, double-blind, randomized, intra-subject placebo-controlled, multiple dose study of QR-313 evaluating safety, proof of mechanism, preliminary efficacy and systemic exposure in subj...
    Medical condition: Recessive Dystrophic Epidermolysis Bullosa (RDEB) due to mutation(s) in exon 73 of the COL7A1 gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Prematurely Ended) CZ (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004365-16 Sponsor Protocol Number: 402-C-1602 Start Date*: 2017-06-09
    Sponsor Name:Reata Pharmaceuticals, Inc.
    Full Title: An extended Access Program to Assess Long-Term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension
    Medical condition: Pulmonary Hypertension
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) BE (Completed) CZ (Completed) GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001052-18 Sponsor Protocol Number: 010 Start Date*: 2020-03-25
    Sponsor Name:Regents of the University of Minnesota
    Full Title: A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for European U...
    Medical condition: Influenza COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) DE (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-001785-26 Sponsor Protocol Number: 14-505 Start Date*: 2016-02-15
    Sponsor Name:Portola Pharmaceuticals, Inc.
    Full Title: Prospective, Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who Have Acute Major Bleeding (ANNEXA-4).
    Medical condition: Uncontrolled bleeding in patients who have taken either a direct factor Xa inhibitor (novel oral anticoagulants) or an indirect factor Xa inhibitor (low molecular weight heparins).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000022097 10075279 Anticoagulant reversal therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) BE (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003490-10 Sponsor Protocol Number: ECR-GLC-2013-06 Start Date*: 2013-09-27
    Sponsor Name:AIBILI (EVICR.net)
    Full Title: Intraocular pressure and tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or preservative free Latanoprost 0.005% Unit Dose (LUDPF) (Monoprost®) in patients with Ocular h...
    Medical condition: Ocular hypertension and glaucoma.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    16.0 10015919 - Eye disorders 10018304 Glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) PT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005557-73 Sponsor Protocol Number: I10E-1302 Start Date*: 2014-10-21
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: An international, multicentre, efficacy and safety study of I10E in initial and maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy
    Medical condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-008336-85 Sponsor Protocol Number: MO22225 Start Date*: 2009-06-05
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A single-arm Phase II clinical study of the combination of carboplatin and weekly paclitaxel plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer
    Medical condition: Epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    9.1 10016180 Fallopian tube cancer LLT
    9.1 10061344 Peritoneal neoplasm LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) NL (Completed) GB (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012086-66 Sponsor Protocol Number: T05018-1001 Start Date*: 2009-12-01
    Sponsor Name:Grifols Inc
    Full Title: A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Stroke
    Medical condition: Thrombus in acute ischemic stroke of the middle cerebral artery
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10008190 Cerebrovascular accident PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) SK (Completed) AT (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2008-001551-22 Sponsor Protocol Number: TRIO 014 Start Date*: 2008-10-21
    Sponsor Name:Cancer International Research Group
    Full Title: A randomized, double-blind, placebo controlled, multicenter, phase II study of adding AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) to first...
    Medical condition: Optimally debulked epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002199-88 Sponsor Protocol Number: NN8022-1922 Start Date*: 2008-12-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes A 56 week randomised, double-blind, placebocontrolled, three armed parallel group, multi-centre, multina...
    Medical condition: Obesity and overweight
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    14.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) ES (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011504-36 Sponsor Protocol Number: AL0906rP Start Date*: 2010-02-02
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: Randomised double blind placebo controlled pivotal study to evaluate efficacy and safety of rPhleum in adult and adolescent patients suffering from rhinoconjunctivitis +/- controlled Asthma
    Medical condition: ICD classification code: J45.0 and J 30.1 Rhiniconjunctivitis +/- asthma bronchiale
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PL (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002396-99 Sponsor Protocol Number: NN7170-4213 Start Date*: 2016-10-20
    Sponsor Name:Novo Nordisk A/S
    Full Title: Safety, tolerability, and pharmacokinetics study of single and multiple subcutaneous doses of turoctocog alfa pegol in patients with haemophilia A
    Medical condition: Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018938 Haemophilia A (Factor VIII) LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: AT (Completed) DE (Completed) BG (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-007416-15 Sponsor Protocol Number: VX08-770-102 Start Date*: 2009-08-11
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX 770 in Subjects with Cystic Fibrosis and the G551D Mutation
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-012997-11 Sponsor Protocol Number: VX08-770-105 Start Date*: 2010-08-25
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: An Open-Label, Rollover Study to Evaluate the Long Term Safety and Efficacy of VX 770 in Subjects with Cystic Fibrosis
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011762 Cystic fibrosis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) IE (Completed) CZ (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002326-11 Sponsor Protocol Number: ET-C-002-07 Start Date*: 2008-10-22
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis®) versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients with Translocation-Related Sarcomas (TRS)
    Medical condition: Translocation-Related Sarcomas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017950-11 Sponsor Protocol Number: ING113086 Start Date*: 2010-11-10
    Sponsor Name:ViiV Healthcare S.L
    Full Title: Estudio fase III, aleatorizado, doble ciego, para evaluar la eficacia y la seguridad de 50 mg de GSK1349572 una vez al día, frente a 400mg de raltegravir dos veces al día, ambos administrados con u...
    Medical condition: Pacientes adultos infectados por el VIH-1 que no han recibido tratamiento antirretroviral previo
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008922 Chronic infection with HIV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002185-78 Sponsor Protocol Number: NER1006-02/2014 Start Date*: 2014-10-10
    Sponsor Name:Norgine Ltd
    Full Title: A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) versus MOVIPREP® using a 2...
    Medical condition: Bowel cleansing prior to any procedure that requires a clean bowel, e.g. colonoscopy, surgical, video capsule or radiological procedures.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10066943 Bowel preparation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-006079-19 Sponsor Protocol Number: RE05 Start Date*: 2007-04-02
    Sponsor Name:University College London
    Full Title: A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10038407 Renal cell cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) BE (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003193-17 Sponsor Protocol Number: BAY86-5321/17514 Start Date*: 2016-08-30
    Sponsor Name:Bayer AG
    Full Title: A multi center, single arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion
    Medical condition: Macular edema secondary to CRVO
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10025415 Macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) DK (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 331  332  333  334  335  336  337  338  339  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 12 15:45:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA